ilShinbiobase
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
ilShinbiobase makes specialist laboratory equipment, ultra-low-temperature freezers that preserve biological samples and freeze dryers that remove moisture from sensitive materials such as pharmaceuticals and food products.
Its customers include biotechnology research laboratories and food and pharmaceutical manufacturers that depend on this equipment for both research and production. Listed on KOSDAQ, Korea's tech and small-cap board, the company handles overseas sales and marketing of its products through a dedicated subsidiary.
Summary is AI-generated and may contain errors · figures from DART filings
Its subsidiary ISC is a specialist export arm that manages all international sales and marketing on behalf of the parent company.
ilShinbiobase in five facts
What does ilShinbiobase do?
ilShinbiobase makes specialist laboratory equipment, ultra-low-temperature freezers that preserve biological samples and freeze dryers that remove moisture from sensitive materials such as pharmaceuticals and food products.
Where is ilShinbiobase listed and in which sector?
ilShinbiobase (Korean name: 일신바이오) trades under KRX code 068330 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Industrials sector, Machinery.
How large is ilShinbiobase?
Its market capitalisation was US$32.9M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were ilShinbiobase's latest annual revenue and operating profit?
For fiscal year 2025, ilShinbiobase reported revenue of US$11M, operating profit of US$3.4M and net income of US$3.6M, per its annual report on DART (data retrieved from DART on 2026-09-17). Revenue was up 34.3% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-17
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- [Amended] Half-year report (2026.06)Oct 8
- Supply contract signed (voluntary)
ilShinbiobase disclosed a supply contract with Ildong Bioscience Co., Ltd., worth US$715K, about 6.61% of its recent annual revenue, running through Mar 2027.
Supply contract · Oct 2 - [Amended] Supply contract signed
ilShinbiobase updated a previously disclosed supply contract with an individual, now worth US$1.66M, about 20.8% of its recent annual revenue, running through Dec 2026.
Supply contract · Sep 30 · 2 versions - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
ilShinbiobase reported separate results for FY2025: revenue of US$10.1M (+34.3% year on year), operating profit of US$3.16M (+101% year on year) and net income of US$3.38M (+27.8% year on year).
Earnings · Feb 13 - Cash/in-kind dividend decision
ilShinbiobase declared a cash dividend of US$0.01 per share.
Dividend · Feb 13 - Supply contract signedSupply contract · Jan 28